Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Infliximab for the Treatment of Sterile Corneal Melt
NCT02987686Phase 1Completed
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Sep 2017
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of infliximab in Sterile corneal melt (2 arms), sponsored by Centre hospitalier de l’Université de Montréal. Primary endpoints: Adverse Events at 12 weeks and Percentage of patients finishing 4 weeks of infliximab use. Started Sep 2017; status: completed.
02
Drugs
infliximab
03
Conditions
Sterile corneal melt
Beyond the preview
Go deeper on NCT02987686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02987686.